JNJ

227.5

-0.9%↓

ABT

91.43

+0.09%↑

MDT

82.96

-0.35%↓

A

115.22

+0.92%↑

VEEV

158.38

+1.6%↑

JNJ

227.5

-0.9%↓

ABT

91.43

+0.09%↑

MDT

82.96

-0.35%↓

A

115.22

+0.92%↑

VEEV

158.38

+1.6%↑

JNJ

227.5

-0.9%↓

ABT

91.43

+0.09%↑

MDT

82.96

-0.35%↓

A

115.22

+0.92%↑

VEEV

158.38

+1.6%↑

JNJ

227.5

-0.9%↓

ABT

91.43

+0.09%↑

MDT

82.96

-0.35%↓

A

115.22

+0.92%↑

VEEV

158.38

+1.6%↑

JNJ

227.5

-0.9%↓

ABT

91.43

+0.09%↑

MDT

82.96

-0.35%↓

A

115.22

+0.92%↑

VEEV

158.38

+1.6%↑

Search

Treace Medical Concepts Inc

Atvērts

1.88 1.08

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

1.73

Max

1.9

Galvenie mērījumi

By Trading Economics

Ienākumi

6.9M

-9.4M

Pārdošana

12M

63M

Peļņas marža

-15.026

Darbinieki

450

EBITDA

7M

-5.2M

Rekomendācijas

By TipRanks

Rekomendācijas

Neitrāls

Prognoze 12 mēnešiem

+118.18% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2026. g. 7. maijs

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-448K

128M

Iepriekšējā atvēršanas cena

0.8

Iepriekšējā slēgšanas cena

1.88

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bullish Evidence

Treace Medical Concepts Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 24. apr. 00:00 UTC

Peļņas

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

2026. g. 24. apr. 00:00 UTC

Peļņas

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

2026. g. 23. apr. 23:47 UTC

Tirgus saruna

Gold Edges Lower Amid Ongoing Concerns Over Higher Inflation -- Market Talk

2026. g. 23. apr. 23:43 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 23. apr. 23:43 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 23. apr. 23:43 UTC

Tirgus saruna

Nikkei May Decline Amid Uncertainty Over U.S.-Iran Conflict -- Market Talk

2026. g. 23. apr. 23:13 UTC

Iegādes, apvienošanās, pārņemšana

Trump on Spirit Airlines: 'I Think We'd Just Buy It' -- Update

2026. g. 23. apr. 22:33 UTC

Peļņas

Intel Shares Jump 20% as AI Agents Drive Big Growth -- WSJ

2026. g. 23. apr. 22:17 UTC

Peļņas

PLS Executed Offtake Agreement With Ronbay

2026. g. 23. apr. 22:17 UTC

Peļņas

PLS Secured Up to A$38.1M in Australia Government ARENA Grant Funding

2026. g. 23. apr. 22:16 UTC

Peļņas

PLS Commences Commissioning of Midstream Demonstration Plant

2026. g. 23. apr. 22:15 UTC

Peļņas

PLS Group Reaffirms FY26 Guidance for All Metrics

2026. g. 23. apr. 22:14 UTC

Peļņas

PLS Group 3Q Cash Margin From Operations A$461M at March 31

2026. g. 23. apr. 22:14 UTC

Peļņas

PLS Group 3Q Cash Balance A$1.455 Billion at March 31

2026. g. 23. apr. 22:13 UTC

Peļņas

PLS Group 3Q Unit Operating Cost A$733/Ton CIF, Up 2% on 2Q

2026. g. 23. apr. 22:12 UTC

Peļņas

Correct: PLS Group 3Q Unit Operating Cost A$520/Ton FOB, Down 11% on 2Q

2026. g. 23. apr. 22:12 UTC

Peļņas

PLS Group 3Q Unit Operating Cost US$520/Ton FOB, Down 11% on 2Q

2026. g. 23. apr. 22:11 UTC

Peļņas

PLS Group 3Q Realized Price US$1,867/Ton, Up 61% on 2Q

2026. g. 23. apr. 22:10 UTC

Peļņas

PLS Group 3Q Revenue A$567,000, Up 52% on 2Q

2026. g. 23. apr. 22:09 UTC

Peļņas

PLS Group 3Q Sales 195,700 Tons, Down 16% on 2Q

2026. g. 23. apr. 22:08 UTC

Peļņas

PLS Group 3Q Production 232,400 Tons, Up 12% on 2Q

2026. g. 23. apr. 22:04 UTC

Peļņas

Intel Sales Rise 7% as AI Agents Drive Growth -- WSJ

2026. g. 23. apr. 21:56 UTC

Tirgus saruna
Peļņas

Intel Points to Growing Role of CPUs Amid AI Shifts -- Market Talk

2026. g. 23. apr. 21:48 UTC

Iegādes, apvienošanās, pārņemšana

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

2026. g. 23. apr. 21:27 UTC

Peļņas

Intel CFO: All Demand Signals Point to Growing Role of CPUs in AI Era

2026. g. 23. apr. 21:25 UTC

Peļņas

Intel CFO Expects Factories to Continue Increasing Supply in 3Q, 4Q, but at More Measured Pace Than Previously Expected

2026. g. 23. apr. 21:24 UTC

Peļņas

SAP Stock Rebounds From Software Slaughter. The Cloud Boosted Europe's Tech Titan. -- Barrons.com

2026. g. 23. apr. 21:24 UTC

Peļņas

Blackstone Stock Falls After Earnings. Private Credit Remains in Focus. -- Barrons.com

2026. g. 23. apr. 21:21 UTC

Peļņas

Intel to Look for Unconventional Way to Boost Manufacturing Capacity Through Musk's Terafab Project, CEO Says

2026. g. 23. apr. 21:21 UTC

Peļņas

Intel CEO: He, Elon Musk Believe Global Semiconductor Supply Isn't Keeping Up With Accelerating Demand

Salīdzinājums

Cenas izmaiņa

Treace Medical Concepts Inc Prognoze

Cenas mērķis

By TipRanks

118.18% augšup

Prognoze 12 mēnešiem

Vidējais 4.08 USD  118.18%

Augstākais 7 USD

Zemākais 2.25 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Treace Medical Concepts Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

4 ratings

1

Pirkt

3

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

7.16 / 7.65Atbalsts un pretestība

Īstermiņā

Strong Bullish Evidence

Vidējā termiņā

Bearish Evidence

Ilgtermiņā

Bullish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Treace Medical Concepts Inc

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.
help-icon Live chat